FoldRx Pharmaceuticals

FoldRx Pharmaceuticals was a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class small molecule therapeutics for diseases caused by protein misfolding. The company utilized a proprietary yeast-based drug discovery platform to identify compounds that restore proper protein folding or stabilize correctly folded proteins. Its lead candidate, Vyndaqel (tafamidis), was developed as a first-in-class oral therapy for transthyretin amyloid polyneuropathy (ATTR-PN). Beyond its lead program, FoldRx maintained research efforts in cystic fibrosis and neurodegenerative diseases like Parkinson's. The company was acquired by Pfizer in 2010, which led to the successful global commercialization of tafamidis.